Point72 Asset Management L.P. Buys Shares of 700,987 Savara Inc (NASDAQ:SVRA)

Point72 Asset Management L.P. purchased a new stake in shares of Savara Inc (NASDAQ:SVRA) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 700,987 shares of the company’s stock, valued at approximately $2,152,000. Point72 Asset Management L.P. owned approximately 0.41% of Savara at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in SVRA. JPMorgan Chase & Co. boosted its stake in shares of Savara by 23.9% during the third quarter. JPMorgan Chase & Co. now owns 69,490 shares of the company’s stock valued at $295,000 after purchasing an additional 13,420 shares in the last quarter. SG Americas Securities LLC boosted its stake in shares of Savara by 14.0% during the fourth quarter. SG Americas Securities LLC now owns 51,589 shares of the company’s stock valued at $158,000 after purchasing an additional 6,330 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in shares of Savara by 14.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 36,390 shares of the company’s stock valued at $112,000 after purchasing an additional 4,732 shares in the last quarter. Rhumbline Advisers boosted its stake in shares of Savara by 6.8% during the fourth quarter. Rhumbline Advisers now owns 141,425 shares of the company’s stock valued at $434,000 after purchasing an additional 9,041 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in shares of Savara by 7.6% during the fourth quarter. Bank of New York Mellon Corp now owns 253,630 shares of the company’s stock valued at $779,000 after purchasing an additional 17,870 shares in the last quarter. 87.93% of the stock is owned by institutional investors and hedge funds.

Savara Price Performance

Savara stock opened at $3.13 on Wednesday. The stock’s 50 day moving average is $2.96 and its 200 day moving average is $3.01. The company has a debt-to-equity ratio of 0.13, a current ratio of 17.70 and a quick ratio of 17.70. The firm has a market cap of $540.98 million, a P/E ratio of -7.28 and a beta of 0.44. Savara Inc has a one year low of $2.26 and a one year high of $5.11.

Savara (NASDAQ:SVRA) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.12) EPS for the quarter, hitting analysts’ consensus estimates of ($0.12). As a group, research analysts expect that Savara Inc will post -0.45 EPS for the current year.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and set a $6.00 price target on shares of Savara in a research note on Friday, March 28th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $8.83.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.